Encefalopatías y encefalitis durante la infección aguda por SARS-CoV2. Registro de la Sociedad Española de Neurología SEN COVID-19 / Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry

OBJETIVOS: Desde el inicio de la pandemia por el virus SARS-CoV2 la Sociedad Española de Neurología (SEN) creó un registro de afectación neurológica para informar al neurólogo clínico. Las encefalopatías y encefalitis fueron una de las complicaciones más descritas. Analizamos las características de las mismas. PACIENTES Y MÉTODOS: Estudio descriptivo retrospectivo, observacional multicéntrico, de pacientes con sintomatología compatible con encefalitis o encefalopatía, introducidos en el Registro SEN COVID-19 desde el 17 de marzo hasta el 6 de junio de 2020. RESULTADOS: Se han registrado 232 casos con síntomas neurológicos, 51 casos de encefalopatía/encefalitis (21,9%). Ningún paciente era trabajador sanitario. Los síndromes más frecuentes fueron: cuadro confusional leve-moderado (33%) y encefalopatía grave o coma (9,8%). El tiempo medio entre el inicio de la infección y la clínica neurológica fue de 8,02 días. Punción lumbar en el 60,8% de pacientes; solo hubo un caso con PCR positiva. Resonancia craneal en el 47% de los pacientes (alterada en el 7,8% de ellos). Se realizó electroencefalograma en el 41,3% de los casos (alterado en el 61,9% de los mismos). CONCLUSIONES: Las encefalopatías y encefalitis son dos de las complicaciones más frecuentes descritas en el SEN COVID-19. Más de un tercio de los pacientes presentó un cuadro de síndrome confusional leve o moderado. El tiempo medio de aparición de la sintomatología neurológica desde el inicio de la infección fue de 8 días (hasta 24 h antes en mujeres que en hombres). El electroencefalograma fue la prueba más sensible en estos pacientes, encontrando muy pocos casos con alteraciones en las pruebas de neuroimagen. Todos los pacientes que recibieron tratamiento con bolos de corticoides o inmunoglobulinas tuvieron una evolución favorable

OBJECTIVES: Since the beginning of the COVID-19 pandemic, the Spanish Society of Neurology has run a registry of patients with neurological involvement for the purpose of informing clinical neurologists. Encephalopathy and encephalitis were among the most frequently reported complications. In this study, we analyse the characteristics of these complications. PATIENTS AND METHODS: We conducted a retrospective, descriptive, observational, multicentre study of patients with symptoms compatible with encephalitis or encephalopathy, entered in the Spanish Society of Neurology's COVID-19 Registry from 17 March to 6 June 2020. RESULTS: A total of 232 patients with neurological symptoms were registered, including 51 cases of encephalopathy or encephalitis (21.9%). None of these patients were healthcare professionals. The most frequent syndromes were mild or moderate confusion (33%) and severe encephalopathy or coma (9.8%). The mean time between onset of infection and onset of neurological symptoms was 8.02 days. Lumbar puncture was performed in 60.8% of patients, with positive PCR results for SARS-CoV-2 in only one case. Brain MRI studies were performed in 47% of patients, with alterations detected in 7.8% of these. EEG studies were performed in 41.3% of cases, detecting alterations in 61.9%. CONCLUSIONS: Encephalopathy and encephalitis are among the complications most frequently reported in the registry. More than one-third of patients presented mild or moderate confusional syndrome. The mean time from onset of infection to onset of neurological symptoms was 8 days (up to 24 hours earlier in women than in men). EEG was the most sensitive test in these patients, with very few cases presenting alterations in neuroimaging studies. All patients treated with boluses of corticosteroids or immunoglobulins progressed favourably

Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry. / Encefalopatías y encefalitis durante la infección aguda por SARS-CoV2. Registro de la Sociedad Española de Neurología SEN COVID-19.

OBJECTIVES: Since the beginning of the COVID-19 pandemic, the Spanish Society of Neurology has run a registry of patients with neurological involvement for the purpose of informing clinical neurologists. Encephalopathy and encephalitis were among the most frequently reported complications. In this study, we analyse the characteristics of these complications. PATIENTS AND METHODS: We conducted a retrospective, descriptive, observational, multicentre study of patients with symptoms compatible with encephalitis or encephalopathy, entered in the Spanish Society of Neurology's COVID-19 Registry from 17 March to 6 June 2020. RESULTS: A total of 232 patients with neurological symptoms were registered, including 51 cases of encephalopathy or encephalitis (21.9%). None of these patients were healthcare professionals. The most frequent syndromes were mild or moderate confusion (33%) and severe encephalopathy or coma (9.8%). The mean time between onset of infection and onset of neurological symptoms was 8.02 days. Lumbar puncture was performed in 60.8% of patients, with positive PCR results for SARS-CoV-2 in only one case. Brain MRI studies were performed in 47% of patients, with alterations detected in 7.8% of these. EEG studies were performed in 41.3% of cases, detecting alterations in 61.9%. CONCLUSIONS: Encephalopathy and encephalitis are among the complications most frequently reported in the registry. More than one-third of patients presented mild or moderate confusional syndrome. The mean time from onset of infection to onset of neurological symptoms was 8 days (up to 24hours earlier in women than in men). EEG was the most sensitive test in these patients, with very few cases presenting alterations in neuroimaging studies. All patients treated with boluses of corticosteroids or immunoglobulins progressed favourably.

[Impact of the COVID-19 pandemic on the training of Spanish neurology residents]. / Repercusión de la pandemia por COVID-19 en la formación de los residentes de neurología españoles.

Introduction: The COVID-19 pandemic has transformed medical practice and severely disrupted the training of medical residents worldwide. The Spanish Society of Neurology conducted a study to assess its impact on the training of neurology residents in Spain. Methods: We performed a descriptive, cross-sectional study through a survey distributed by e-mail to all neurology residents belonging to the Society. The survey included questions on demographic variables, care activity, and personal and educational impact of the pandemic, as well as respondents' expectations for the future of their work in the post-pandemic era. Results: Of 422 surveys sent, we received a total of 152 responses (36%); 79 respondents (52%) were women and 73 (48%) were men. By year of residency, 51 respondents (33.6%) were in the fourth year, 45 (29.6%) in the third year, 28 (18.4%) in the second year, and 28 (18.4%) in the first year. A total of 139 respondents (90.8%) reported changes in hospital activity, and 126 (82.8%) considered the situation to have had a negative impact on their training, with 99 (64.7%) having lost non-recoverable rotations. Sixty-six percent of respondents (n=101) expressed a desire to extend their residency period. Conclusions: The pandemic has had an extremely severe impact on all areas of the health system, with trainee physicians being one of the most affected groups. Among neurology residents, the crisis has caused significant shortcomings in their training and clinical activities, through the suspension of specific rotations. A high percentage of respondents wished to extend the residency period.

[Current evidence on virtual reality and its potential usefulness in post-stroke neurorehabilitation]. / Evidencias actuales sobre la realidad virtual y su utilidad potencial en la neurorrehabilitación postictus.

INTRODUCTION: Virtual reality therapy (VRT) constitutes a powerful and motivating tool for stroke patients to actively participate in the process of neurorehabilitation, providing augmented performance feedback, with the aim of achieving better therapeutic results owing to the enhancing of neuroplasticity mechanisms. AIM: To report the most relevant data about the applications of VRT in the post-stroke neurorehabilitation. DEVELOPMENT: We conducted a PubMed search for articles, latest books, leading clinical practice guidelines, and scientific societies, regarding such applications. CONCLUSIONS: Different performed randomized clinical trials (RCT) show that VRT safely facilitates in a statistically significant way motor and functional recovery of upper limb, gait, balance, quality of life related to health, and activities of daily living, together with conventional therapy, but have no clearly demonstrated overall superiority to conventional therapy. In this regard, underlying specific mechanisms remain elusive at this stage. Future RCT should define the good responder stroke patient profile based on the VRT used in conjunction with conventional therapy, allowing the generation of neurorehabilitation approaches that combine a customized immersive VRT with the clinical experience of the therapists, to maximize the results. It is necessary to carry out well-designed RCT, including larger samples of appropriately selected stroke subjects, to draft a consensus document that allows recommending, with a greater level of evidence and on a widespread basis, the implementation of VRT as add-on therapy in post-stroke neurorehabilitation. As well as to determine if the beneficial effects are maintained in the long term and to clarify the most suitable treatment schedule.

TITLE: Evidencias actuales sobre la realidad virtual y su utilidad potencial en la neurorrehabilitación postictus.Introducción. La terapia con realidad virtual (TRV) constituye una herramienta poderosa que motiva a los pacientes con ictus a participar activamente en su neurorrehabilitación, y proporciona retroalimentación aumentada del rendimiento, con objeto de obtener mejores resultados terapéuticos gracias a la potenciación de los mecanismos de neuroplasticidad. Objetivo. Exponer los datos más relevantes sobre las aplicaciones de la TRV en la neurorrehabilitación postictus. Desarrollo. Búsqueda de artículos en PubMed, últimos libros y principales guías de práctica clínica y sociedades científicas publicados con respecto a dichas aplicaciones. Conclusiones. Los diferentes ensayos clínicos aleatorizados (ECA) realizados demuestran que la TRV facilita, de forma segura y estadísticamente significativa, la recuperación motora y funcional del miembro superior, la marcha, el equilibrio, la calidad de vida relacionada con la salud y las actividades de la vida diaria, junto con la terapia convencional, sin ser globalmente superior a la terapia convencional. Aún no se conocen los mecanismos específicos subyacentes. Los ECA futuros deberán definir el perfil de paciente respondedor según la TRV empleada, permitiendo generar enfoques de neurorrehabilitación que conjuguen una TRV personalizada inmersiva y la experiencia clínica de los terapeutas para maximizar los resultados. Son precisos ECA bien diseñados, incluyendo muestras amplias de pacientes adecuadamente seleccionados, para redactar un documento de consenso que permita recomendar, con un mayor nivel de evidencia y de forma generalizada, la implementación de la TRV como terapia complementaria en la neurorrehabilitación postictus, determinar si los efectos beneficiosos se mantienen a largo plazo y clarificar qué esquema de tratamiento es el más apropiado.

Propiedades métricas de la versión española del Cuestionario de Mal de Altura del Lago Louise / Metric properties of the Spanish version of the Lake Louise Acute Mountain Sickness Questionnaire

Objetivos: Evaluar las propiedades métricas de la versión española del Cuestionario de Mal de Altura del Lago Louise (CMALL) autoaplicado de 5 ítems. Métodos: Tras el curso-seminario «Neurociencia en las culturas andinas precolombinas» (Perú, 2009), se entregó una encuesta a los participantes que incluía el CMALL. Se evaluó la aceptabilidad de los ítems (puntuaciones observadas vs valores posibles, efectos techo y suelo), asunciones escalares (correlación ítem-total > 0,30), consistencia interna (alfa de Cronbach), precisión (error estándar de la medida) y validez de convergencia y discriminante. Esta última se evaluó calculando el valor medio del CMALL entre aquellos neurólogos que creían haber presentado mal de altura frente a quienes no lo habían presentado. Resultados: Estancia por días en altura: Cuzco 3.400 m sobre el nivel del mar (msnm), Valle Sagrado (2.850 msnm) y Machu Picchu (2.450 msnm). Se incluyeron 70 sujetos (60% varones, edad media 50±8 años, 88,6% neurólogos). El valor medio del CMALL fue 3,36±2,02 (mediana 3, asimetría 0,61). Los efectos techo y suelo fueron 7,3 y 1,4%. El alfa de Cronbach fue 0,61 y el error estándar de la medida 1,26. El CMALL se correlacionó significativamente (r=0,41, p=0,002) con los ítems de exploración física (ataxia, disnea, temblor, síntomas mentales). Las puntuaciones del CMALL fueron significativamente mayores (peores) en quienes presentaron mal de altura (5,8 vs 3,0; Mann-Whitney, p<0,0001). Conclusiones: Las propiedades métricas de la versión española del CMALL parecen ser adecuadas. Este cuestionario puede ser útil en la detección precoz del mal de altura (AU)

Abstract: Objectives: To assess the metric properties of the Lake Louise Acute Mountain Sickness (LLAMSQ) five-item questionnaire. Methods: At the end of the course ‘‘Neuroscience in pre-Columbian Andean cultures’’ (Peru, 2009), the participants answered the self-reported version of the LLAMSQ. The following psychometric attributes were explored: acceptability (observed versus possible scores; floor and ceiling effects), scaling assumptions (item-total correlation > 0.30), internal consistency (Cronbach ˇıs alpha), precision (standard error of measurement), and convergent and discriminative validity. Differences in mean score of LLAMSQ between symptomatic acute mountain sickness subjects and asymptomatic ones were calculated. Results: The participants stayed for days at Cuzco (3,400 meters above sea level, MASL), Sacred valley (2,850 MASL) and Machu Picchu (2,450 MASL). Seventy people (60% males; mean age 50±8 years; 88.6% neurologists) were included in the study. LLAMSQ mean score was 3.36±2.02 (median 3; skewness 0.61). Ceiling and floor effects were 7.3% and 1.4%, respectively. Cronbachˇıs alpha was 0.61, and standard error of measurement 1.26. LLAMSQ mean score significantly correlated (r = 0.41, P = .002) with physical items (ataxia, dyspnoea, tremor, mental symptoms). LLAMSQ mean scores were significantly higher (worse) in those subjects who presented with acute sickness mountain (5.8 vs 3.0; Mann-Whitney, P < .0001). Conclusions: Metric properties of the LLASMQ Spanish version are adequate. This questionnaire seems to be useful in the early detection of high-altitude illness (AU)

Metric properties of the Spanish version of the Lake Louise Acute Mountain Sickness Questionnaire.

OBJECTIVES: To assess the metric properties of the Lake Louise Acute Mountain Sickness (LLAMSQ) five-item questionnaire. METHODS: At the end of the course "Neuroscience in pre-Columbian Andean cultures" (Peru, 2009), the participants answered the self-reported version of the LLAMSQ. The following psychometric attributes were explored: acceptability (observed versus possible scores; floor and ceiling effects), scaling assumptions (item-total correlation > 0.30), internal consistency (Cronbach́s alpha), precision (standard error of measurement), and convergent and discriminative validity. Differences in mean score of LLAMSQ between symptomatic acute mountain sickness subjects and asymptomatic ones were calculated. RESULTS: The participants stayed for days at Cuzco (3,400 meters above sea level, MASL), Sacred valley (2,850 MASL) and Machu Picchu (2,450 MASL). Seventy people (60% males; mean age 50±8 years; 88.6% neurologists) were included in the study. LLAMSQ mean score was 3.36±2.02 (median 3; skewness 0.61). Ceiling and floor effects were 7.3% and 1.4%, respectively. Cronbach́s alpha was 0.61, and standard error of measurement 1.26. LLAMSQ mean score significantly correlated (r=0.41, P=.002) with physical items (ataxia, dyspnoea, tremor, mental symptoms). LLAMSQ mean scores were significantly higher (worse) in those subjects who presented with acute sickness mountain (5.8 vs 3.0; Mann-Whitney, P<.0001). CONCLUSIONS: Metric properties of the LLASMQ Spanish version are adequate. This questionnaire seems to be useful in the early detection of high-altitude illness.